We are a leader in the application of advanced AI to accelerate biopharma drug discovery.

BenevolentAI_AI-Enabled_Drug_Discovery_.jpg

ABOUT US

AI-enabled drug discovery

We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery.
The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases.

We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

Benevolent Platform
 

Progress

End-to-end drug discovery offerings

We are continuing to expand on our industry-leading collaborations further validating our drug discovery offerings and end-to-end drug discovery offerings
 

End-to-End Drug Discovery

Preclinical & clinical development pipeline

We are progressing five of our most advanced high-potential clinical and preclinical assets to their next inflection points. Lead asset, BEN-8744, for the treatment of ulcerative colitis is in a Phase I clinical study with topline data readout expected Q1 2024

Pipeline

New Knowledge Exploration tools

Our new  customisable SaaS products enable scientists to make higher-confidence decisions and improve discovery and research productivity. The two key products are BenAI-Q and BenAI Research Assistant with initial product development substantially completed and user testing underway

Knowledge Exploration

Multi-year collaboration with AstraZeneca continues to progress

AstraZeneca is progressing four of the most promising targets selected into the AstraZeneca portfolio in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) while good progress is being made toward further target selections in Heart Failure and SLE

Astrazeneca
 

New strategic collaboration with Merck

Multi-year collaboration to identify and develop innovative compounds, initially for three novel small molecule drug candiates in in oncology, neurology and immunology

Merck
 

BenevolentAI___AstraZeneca__Fusing_AI_and_Drug_Discovery_Expertise_to_Find_New_Treatments_for_CKD.jpg

Partner with us

We work with leading biopharma companies to discover innovative therapeutics

We partner with biopharma companies to discover novel treatments using the Benevolent Platform™. Our expertise spans across the entire drug discovery and development process and we can work on any therapeutic area or drug modality.

Work with us

Homepage-Careers.jpg

Careers

A diverse team passionate about building a healthier future

BenevolentAI embodies a new type of culture based on true collaboration between scientists and technologists who work together to redefine how drugs are discovered and developed. If you are curious and collaborative and want to help shape the future of new discoveries, we would love to hear from you.

Join us

Our offices

Our_Offices_London.jpg
London | Headquarters

4-8 Maple Street
London W1T 5HD

Our_Offices_NY.jpg
New York | Office

15 MetroTech Center
8th FL, Brooklyn
NY 11201

Our_Offices_Cambridge.jpg
Cambridge | Wet Labs

Babraham Campus
Cambridge CB22 3AT